{"id":"NCT03726879","sponsor":"Hoffmann-La Roche","briefTitle":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-11","primaryCompletion":"2021-02-05","completion":"2023-08-24","firstPosted":"2018-11-01","resultsPosted":"2022-03-25","lastUpdate":"2024-11-05"},"enrollment":454,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":["Adriamycin"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Cytoxan","Neosar"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["Taxol"]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin"]},{"type":"DRUG","name":"Pertuzumab","otherNames":["Perjeta"]},{"type":"DRUG","name":"Trastuzumab Emtansine","otherNames":["Kadcyla"]}],"arms":[{"label":"Atezolizumab +ddAC-PacHP","type":"EXPERIMENTAL"},{"label":"Placebo + ddAC-PacHP","type":"PLACEBO_COMPARATOR"}],"summary":"This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).","primaryOutcome":{"measure":"Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)","timeFrame":"From randomization to approximately 6 months","effectByArm":[{"arm":"Atezolizumab +ddAC-PacHP","deltaMin":64.2,"sd":null},{"arm":"Placebo + ddAC-PacHP","deltaMin":72.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1846"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":13},"locations":{"siteCount":76,"countries":["United States","Brazil","Canada","Czechia","Germany","Italy","Japan","Poland","Russia","South Korea","Spain","Taiwan"]},"refs":{"pmids":["35763704"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":226},"commonTop":["Alopecia","Diarrhoea","Nausea","Anaemia","Asthenia"]}}